Skip to content

8:45 am Chair’s Opening Remarks

  • Chad May Senior Vice President - Research & Development, Maverick Therapeutics

Analyzing Target Selection to Maximize Efficacy Whilst Minimizing Toxicity

9:00 am TriTACs – Development Challenges and Opportunities for Novel T Cell Engagers


• T cell engager background: work well in liquid tumors, limited success in solid tumors so far
• Analysis of differences: targets space, tumor microenvironment, drug exposures
• Considerations for target selection and platform design to address these challenges
• Description of the TriTAC platform
• End with an update on the lead program, HPN424, currently in the clinic for the treatment of prostate cancer

9:30 am A Novel Class of NK-cell Engagers for Tumor Targeting

  • Michael Schmidt Vice President - Antibody Discovery & Engineering, Compass Therapeutics


• Compass Tx has developed a NK-cell engager platform targeting various tumor antigens
• NK-cell engagers bind to tumor antigens on tumor cells and to NKp30 and CD16A (FcgRIIIA) on NK cells, specifically redirecting NK cells towards tumor cells
expressing low level of tumor antigen

10:00 am The ImmTAC™ Platform: Progress and Clinical Insight from the Soluble TCR-based Bispecific Approach

  • Joseph Dukes Director, Program Leader & Head of Preclinical Biology, Immunocore Ltd


• Introduce the ImmTAC platform and discuss the potential benefits of TCR-based targeting
• Present clinical data and learnings from trials with IMCgp100, the lead ImmTAC in pivotal/Ph3 trials
• Update on the pipeline with some preclinical data on ImmTAC reagents in early stage clinical trials

10:30 am Exploiting the Interplay of Innate, Humoral, and Cellular Immunity


• Need to engage multiple arms of the immune systems while overcoming
immunosuppression of tumor microenvironment for highest level of therapeutic efficacy
• Divergent forms of immunotherapy (biologic cell engagers/antibodies, adoptive
cell therapy or combination therapies) all require sophisticated cell engineering
for first-in-class execution
• Case studies highlighting clinical-scale engineering for:

  • Production of cell engagers & novel protein formats for fine-tuning in vivo
    effector function
  • NK cell engineering for improved efficacy of approved mAb therapies
  • Checkpoint gene editing to combat tumor immunosuppression

11:00 am Morning Refreshments & Speed Networking

12:00 pm Humabody® VH as T-cell Enhancing Therapeutics for Immuno Oncology


• Not all T cell bispecifics are equal
• Considerations for safer and more durable anti-cancer immune responses
• Humabody® VH Platform – Strengths and challenges of the Humabody® VH Platform
• PSMA-CD137 multispecific Humabody® – the frontrunner into the clinic

Discovering the Importance of Understanding Cell Engager Mechanisms

12:30 pm Testing Efficacy and Safety of Ovarian-Cancer Targeted Bispecific Antibodies in Mouse and Cynomolgus Monkey Models


• Development of unique immunocompetent murine models to simultaneously investigate effects of CD3-bispecifics on tumors and normal tissues
• Using iPET imaging to understand localization of bispecific antibodies in these unique murine models

1:00 pm Lunch & Networking

2:00 pm Mechanisms of Bispecific T cell Engager Efficacy and Toxicity in Murine Tumor Models

  • Charles Sentman Director - Center for Synthetic Immunity & Professor, Geisel School of Medicine at Dartmouth


• Efficacy and mechanisms of action against lymphoma
• Efficacy and mechanisms of action against metastatic melanoma
• Mechanisms associated with acute off-tumor toxicity

2:30 pm ACC (Antibody Cell Conjugation) to Chemically Conjugate Antibodies to NK or T Cells Without Genetic Engineering


  • ACC-NK cells retain antibodies binding ability
  • ACC-NK in vivo xenograft models of liquid tumors and solid tumors
  • Mechanism of ACC-NK, and ACC-NK’s performance in tumor micro-environment

3:00 pm Afternoon Refreshments & Poster Session

4:00 pm Round Table Discussion

Analyzing Target Selection

• What is the impact of construct design on bioactivity, safety and efficacy?
• Does variation in affinity for antigens lead to a different outcome in preclinical studies?
• How does CD3 and/or tumor antigen binding affinity affect bioactivity, safety and efficacy?



Discussing Manufacturing Limitations

• What are the difficulties of manufacturing antibodies with bespoke designs?
• Addressing the importance of designing antigens that maintain efficacy when put into cell engager format
• Examining how simple and robust platforms affect manufacturability and the ultimate success of a cell engager


Comparing Cell Engagers with CAR Therapeutics

• Evaluating how the off-the-shelf nature of cell engagers can reduce manufacturing costs and treatments time to create a more available therapeutic
• Verifying how and why the small size of some cell engagers allows for better efficacy in solid tumor indications
• Comparing cell engagers with CAR-T and discussing possible combination therapies

5:00 pm Chair’s Closing Remarks

  • Chad May Senior Vice President - Research & Development, Maverick Therapeutics

5:05 pm End of Day 1